We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Frontier Ip Group Plc | LSE:FIPP | London | Ordinary Share | GB00B63PS212 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -2.38% | 41.00 | 40.00 | 42.00 | 42.00 | 41.00 | 42.00 | 37,003 | 09:57:40 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 372k | -3.24M | -0.0580 | -7.07 | 22.93M |
From May 2019 to May 2024
LONDON-- Intellectual property commercialization specialist Frontier IP Group PLC (FIPP.LN) Monday said its portfolio company Exscientia Ltd yesterday announced that it has entered into a strategic drug discovery collaboration with GlaxoSmithKline PLC (GSK.LN).
Shares at 0801 GMT, up 4 pence, or 11.8%, at 43 pence valuing the company at GBP16.3 million
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
July 03, 2017 04:17 ET (08:17 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Frontier Ip Chart |
1 Month Frontier Ip Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
